Congress:
ECR25
Poster Number:
C-22790
Type:
Poster: EPOS Radiologist (scientific)
Authorblock:
C. Carbone, F. Albisinni, C. Zacchi, A. Dalla Volta, A. Berruti, A. Borghesi, N. Di Meo, D. Farina, M. Ravanelli; Brescia/IT
Disclosures:
Carmela Carbone:
Nothing to disclose
Flavia Albisinni:
Nothing to disclose
Chiara Zacchi:
Nothing to disclose
Alberto Dalla Volta:
Nothing to disclose
Alfredo Berruti:
Nothing to disclose
Andrea Borghesi:
Nothing to disclose
Nunzia Di Meo:
Nothing to disclose
Davide Farina:
Nothing to disclose
Marco Ravanelli:
Nothing to disclose
Keywords:
Bones, MR physics, Oncology, MR, MR-Functional imaging, Diagnostic procedure, Metastases, Neoplasia
WB-MRI demonstrated different patterns of radiological response to the two different therapies. Enzalutamide led to tumor size reduction and increased fat fraction (FF%), suggesting tumor necrosis and bone marrow recovery. In contrast, cabozantinib stabilized lesion size, significantly increased ADC, and maintained stable FF%, indicating enhanced tumor necrosis without changes in bone marrow composition. These differences reflect the distinct mechanisms of action of the two therapies (Fig. 9).